Literature DB >> 3943167

The effects of cyclosporine on acute murine Coxsackie B3 myocarditis.

J B O'Connell, E A Reap, J A Robinson.   

Abstract

The effects of the immunosuppressant drug cyclosporine were studied in the murine model of Coxsackie B3 myocarditis. Ten BALB/c mice, given daily cyclosporine (15 mg/kg) intraperitoneally but not infected, were normal in all respects after 2 weeks. All 32 BALB/c mice infected, but given no cyclosporine, survived and had moderate myocardial mononuclear infiltrates and minimal necrosis at 7 and 14 days. In contrast, 24 mice concurrently infected and given cyclosporine had a high mortality rate (75%) and a significantly attenuated mononuclear infiltrate in the presence of enhanced necrosis when compared with control infected mice. Sixteen mice started on the drug 1 week after infection had a lower mortality rate (55%), but very similar histologic abnormalities. In contrast to negligible or no virus in the hearts of infected mice that were not given cyclosporine, drug treated, infected groups had easily detectable virus in their hearts 14 days after infection. An identical study in Swiss ICR mice yielded similar results. Cyclosporine, when given early during acute murine Coxsackie B3 myocarditis, causes a significant increase in myocardial necrosis and mortality, possibly secondary to enhanced viral survival.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943167     DOI: 10.1161/01.cir.73.2.353

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

Review 1.  Immunomodulating therapy in experimental myocarditis.

Authors:  A Matsumori; C Kawai
Journal:  Springer Semin Immunopathol       Date:  1989

Review 2.  [Therapy of dilated cardiomyopathies with and without inflammation].

Authors:  G Hufnagel; S Pankuweit; B Maisch
Journal:  Med Klin (Munich)       Date:  1998-04-15

3.  Myocarditis and dilated cardiomyopathy.

Authors:  W H Abelmann
Journal:  West J Med       Date:  1989-04

4.  Coxsackievirus B3-induced myocarditis. Autoimmunity is L3T4+ T helper cell and IL-2 independent in BALB/c mice.

Authors:  M Estrin; S A Huber
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

5.  Coxsackievirus B-3 myocarditis. T-cell autoimmunity to heart antigens is resistant to cyclosporin-A treatment.

Authors:  M Estrin; C Smith; S Huber
Journal:  Am J Pathol       Date:  1986-11       Impact factor: 4.307

6.  Verapamil ameliorates the clinical and pathological course of murine myocarditis.

Authors:  R Dong; P Liu; L Wee; J Butany; M J Sole
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 7.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

8.  Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.

Authors:  S Matsui; A Matsumori; Y Matoba; A Uchida; S Sasayama
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  The effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis.

Authors:  H Takada; C Kishimoto; Y Kuroki; I Matsushita; Y Hiraoka; M Kurokawa; H Ochiai; S Sasayama
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

10.  Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3.

Authors:  Y Seko; H Matsuda; K Kato; Y Hashimoto; H Yagita; K Okumura; Y Yazaki
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.